Right now, amid the pandemic, the only positive hope for the coronavirus vaccine is the Oxford University’s coronavirus vaccine. According to the Chairman of the Berkshire Research Ethics Committee, David, which approved the Oxford trial, the coronavirus vaccine could be available as early as September.
“Nobody can put final dates… things might go wrong but the reality is that by working with a big pharma company, that vaccine could be fairly widely available around September and that is the sort of target they are working on,” David Carpenter said.
The UK government and AstraZeneca are supporting the coronavirus vaccine development by the Oxford university’s Jenner Institute. AstraZeneca is having the license of Oxford’s potential coronavirus vaccine.
Oxford’s vaccine is based on a version of common cold, causing infections in chimpanzees. The potential coronavirus vaccine’s name is ChAdOx1 nCoV-19. The vaccine also consists of the genetic material of the protein in the spike of SARS-CoV-2.
As per the researchers of Oxford, this vaccine can provide double immunity against the coronavirus.
UK volunteers injected with the vaccine showed that their body now produces both antibodies and “killer T-cells”, a senior source from the trial was quoted by ‘The Daily Telegraph’ as saying.
This discovery is indeed positive because earlier studies show that antibodies may fade with time but T-cells can stay for years.
On the other hand, the source also warned that the results might be promising but it has not yet been proved that Oxford’s vaccine provides the long-lasting immunity against the deadly virus.
Close to the team, another source also described the presence of both the antibodies and “killer T-cells” as “double defence” against the coronavirus.
Last month the pharmaceutical company said that phase 1 trials were due to finish and phase 3 trial started. This phase will prove the efficacy and safety of the vaccine after being tested to thousand of people.
“The COVID-19 vaccine trial team have been working hard on assessing the safety and immunogenicity of ChAdOx1 nCoV-19, and preparing to assess vaccine efficacy,” Sarah Gilbert, professor of vaccinology at the university’s Jenner Institute who is leading the research, had said back in May.